CRP and hyperlipidemia: Adding glycosaminoglycan induced inhibition of c-reactive protein activity and caused changes in and sero-biochemical parameters of phospholipids and free fatty acids, which indicated this compound to be potentially treatable for mammalian hyperlipidemia [237].